What testosterone level is considered low?

The most commonly used clinical threshold in the United States is 300 ng/dL for total testosterone, as recommended by both the American Urological Association and the Endocrine Society. However, this threshold is based on reference ranges derived from population studies and does not account for individual variation in SHBG, assay method, or symptoms. A man with a total testosterone of 290 ng/dL who has no symptoms of hypogonadism is in a different clinical situation from one with the same number and substantial symptoms. Diagnosis requires both a confirmed low testosterone measurement and symptoms consistent with hypogonadism. Symptoms can include reduced libido, erectile dysfunction, fatigue, loss of morning erections, reduced shaving frequency, decreased muscle strength, and depressed mood, though none of these is specific to low testosterone.

Does losing weight actually raise testosterone?

In men whose low testosterone is secondary hypogonadism driven by obesity, yes, weight loss reliably raises testosterone. The magnitude of the increase depends on how much weight is lost, the pre-weight-loss degree of metabolic dysfunction, and the degree of visceral fat reduction. Bariatric surgery studies in severely obese men have reported some of the largest documented increases, with testosterone levels normalizing in a substantial proportion of men who had clinically low levels before surgery. More modest weight losses produce smaller but still measurable increases. The mechanism involves reduced aromatase activity in visceral fat, rising SHBG, and reduced suppression of the HPG axis. This does not apply to men with primary testicular hypogonadism, where the testes themselves have lost the capacity to produce testosterone regardless of metabolic status.

Is testosterone replacement safe for the heart?

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, provided the most definitive evidence available on this question. It enrolled over 5,000 hypogonadal men with cardiovascular disease or high cardiovascular risk and found that testosterone replacement was non-inferior to placebo on a composite outcome of major adverse cardiovascular events, meaning it did not increase heart attacks, strokes, or cardiovascular death. However, the trial also found higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. These secondary findings are statistically significant and are part of the risk discussion between clinician and patient when considering treatment. Prior concerns about cardiovascular risk from testosterone were based on smaller, shorter studies with more limited power to detect differences in hard outcomes.

How does testosterone connect to insulin resistance?

The relationship operates in both directions. Testosterone supports skeletal muscle mass and insulin-stimulated glucose uptake in muscle. Low testosterone is associated with reduced muscle mass, higher body fat, and worsening insulin sensitivity in observational studies. Studies of androgen deprivation therapy in prostate cancer patients, which reduces testosterone to near-zero levels, consistently show deterioration in insulin sensitivity, increased fat mass, and higher rates of metabolic syndrome. In the other direction, insulin resistance suppresses SHBG production in the liver and may suppress HPG axis pulsatility, both of which reduce circulating testosterone. The clinical implication is that addressing either condition often partially improves the other, and that men presenting with metabolic syndrome should be evaluated for hypogonadism and vice versa.

What is the difference between primary and secondary hypogonadism?

Primary hypogonadism means the problem originates in the testes: they are not producing adequate testosterone despite normal or elevated signals from the pituitary. Laboratory results show low testosterone alongside elevated luteinizing hormone and follicle-stimulating hormone, because the pituitary is working harder to drive unresponsive testes. Causes include Klinefelter syndrome, prior chemotherapy or radiation, mumps orchitis, surgical removal, and severe trauma. Secondary hypogonadism means the problem is in the hypothalamus or pituitary: adequate signals are not being sent to the testes. Laboratory results show low testosterone with low or inappropriately normal luteinizing hormone. Obesity-related hypogonadism is almost always secondary, driven by the HPG suppression mechanisms described in the aromatase and insulin sections above. Secondary hypogonadism is more likely to improve with weight loss than primary, which generally requires replacement therapy.

Does testosterone therapy build muscle and reduce fat?

Testosterone replacement in hypogonadal men produces modest improvements in body composition, primarily through increased lean mass and some reduction in fat mass, but the effects seen at replacement doses in clinical trials are considerably smaller than anecdotal accounts suggest. A meta-analysis of randomized trials found that testosterone replacement produced lean mass increases and fat mass decreases compared with placebo, with effect sizes that were statistically significant but modest in clinical magnitude. Supraphysiological doses, meaning doses above the replacement range, produce larger effects on muscle mass, but such doses are not the standard of care for hypogonadism and carry a different risk profile. The TTrials Physical Function Trial found modest but statistically significant improvements in walking distance in older hypogonadal men, consistent with a real but limited functional benefit at replacement doses.

Testosterone and Metabolic Health: What the Research Shows

Published: May 11, 2026•Updated: May 11, 2026

Research use only. This article discusses compounds that include approved medications, investigational drugs, and research peptides. Material sold for research is not cleared for human administration and is not a substitute for medical advice.

Testosterone occupies an unusual position in men's health research: it is one of the most widely discussed hormones in clinical medicine, yet its relationship with metabolic disease is more complicated than popular accounts suggest. Low testosterone and metabolic dysfunction tend to travel together, but the direction of causation runs both ways. Excess body fat suppresses testosterone production, and low testosterone facilitates further fat accumulation. Untangling this feedback loop, and determining when testosterone replacement actually helps, has been the focus of several major clinical trials over the past decade.

Testosterone physiology: the basics

Testosterone is a steroid hormone synthesized primarily in the Leydig cells of the testes, with smaller amounts produced by the adrenal cortex and, in women, by the ovaries. Its production is regulated by the hypothalamic-pituitary-gonadal axis. The hypothalamus releases gonadotropin-releasing hormone in pulses, which stimulates the anterior pituitary to release luteinizing hormone and follicle-stimulating hormone. Luteinizing hormone is the primary driver of testicular testosterone production.

Most circulating testosterone is bound to proteins in the bloodstream and therefore unavailable to enter cells. Roughly 44 percent is tightly bound to sex hormone-binding globulin, 54 percent is loosely bound to albumin, and only about 2 to 3 percent circulates as free testosterone. Free testosterone and albumin-bound testosterone together are sometimes called bioavailable testosterone. The fraction available to tissues depends heavily on SHBG levels, which are themselves influenced by body weight, insulin levels, thyroid function, and age.

Why SHBG matters in metabolic disease

Elevated insulin suppresses hepatic SHBG production. In men with insulin resistance, SHBG tends to be lower than expected for their age, which means total testosterone can look artificially normal even when the biologically active fraction is reduced. Conversely, men who lose significant weight often see SHBG rise and total testosterone increase, even before any direct effect on testicular production. This is one reason that interpreting a single total testosterone measurement in an obese, insulin-resistant man requires context.

The epidemiology of low testosterone in men

Defining low testosterone precisely is harder than it sounds because reference ranges differ by laboratory, assay method, and the population used to establish the range. The American Urological Association and the Endocrine Society have generally used 300 ng/dL total testosterone as a clinical threshold below which hypogonadism may be diagnosed, though symptoms and clinical context matter as much as any single number.

Total testosterone declines with age at a rate estimated at roughly 1 to 2 percent per year after the mid-thirties in population-based studies. The Massachusetts Male Aging Study, a longitudinal cohort that followed men in the Boston area over multiple decades, found age-associated declines in total and free testosterone across cohort members. However, weight gain and illness accounted for a substantial portion of the apparent age-related decline, suggesting that metabolic health, not age alone, is a major determinant of testosterone levels in middle-aged men.

•The Endocrine Society estimates that symptomatic hypogonadism affects 2 to 6 percent of men broadly, with prevalence rising sharply in older and heavier men
•In men with obesity, prevalence of low testosterone is substantially higher, with some studies reporting rates above 40 percent in severely obese men
•In men with type 2 diabetes, low testosterone is estimated to be present in 25 to 40 percent of cases in studies using LC-MS/MS reference methods
•Secondary hypogonadism, where the problem originates in the hypothalamus or pituitary rather than the testes, is the more common pattern in obese men with metabolic disease
•Primary hypogonadism, where the testes themselves fail to respond to luteinizing hormone, is more associated with aging, prior chemotherapy, or anatomical causes

The bidirectional relationship with obesity and insulin resistance

The connection between low testosterone and metabolic disease is not simply that one causes the other. The two conditions are linked by a reinforcing cycle that makes causation difficult to assign in observational studies.

How excess fat suppresses testosterone

Adipose tissue, particularly visceral fat, expresses aromatase, the enzyme that converts androgens including testosterone into estrogens. In men with large amounts of visceral fat, aromatase activity is elevated, accelerating the conversion of testosterone to estradiol. The resulting lower testosterone and higher estradiol signal the hypothalamus to reduce GnRH pulse frequency, suppressing luteinizing hormone and further reducing testicular output. This mechanism explains why the testosterone suppression seen in obese men typically has the hormonal pattern of secondary hypogonadism rather than primary testicular failure.

How low testosterone promotes fat accumulation

Testosterone promotes the differentiation of mesenchymal stem cells toward muscle and away from adipocytes. It also supports skeletal muscle protein synthesis and maintenance of lean mass. When testosterone is low, the balance shifts: muscle mass declines, resting energy expenditure falls, and fat accumulation accelerates. Animal studies using castration models consistently show increased adiposity, and clinical studies of androgen deprivation therapy in prostate cancer patients, which drives testosterone to near-castrate levels, show rapid increases in fat mass and the metabolic markers associated with insulin resistance.

The insulin connection

Insulin resistance has independent effects on the HPG axis beyond the aromatase pathway. Elevated insulin suppresses SHBG synthesis in the liver, reducing the protein that normally binds and stabilizes circulating testosterone. Separately, some research has suggested that hyperinsulinemia may directly suppress luteinizing hormone pulsatility. The net result is that insulin-resistant men tend to have lower total and free testosterone than expected, with lower SHBG adding to the effect.

Why weight loss improves testosterone

Multiple studies have shown that weight loss consistently raises testosterone in men with obesity-related secondary hypogonadism. The mechanism is largely the reversal of the pathways described above: less visceral fat means less aromatase activity, rising SHBG, and less suppression of the HPG axis. A meta-analysis of bariatric surgery outcomes found substantial testosterone increases following surgically induced weight loss, with some studies showing normalization of previously low levels without any testosterone replacement.

How hypogonadism is diagnosed

Diagnosis requires both biochemical evidence and clinical symptoms. Testing on a single sample is not sufficient because testosterone secretion is pulsatile and peaks in the early morning. Guidelines from the Endocrine Society recommend morning fasting samples drawn between 7 and 10 AM, confirmed by a second measurement if the first is below the clinical threshold, before initiating treatment.

•Total testosterone by liquid chromatography-tandem mass spectrometry is the most accurate measurement method; immunoassay methods commonly used in standard labs have variable accuracy particularly near the lower end of the reference range
•Free testosterone calculated from total testosterone and SHBG using the Vermeulen equation provides a clinically useful estimate when measured free testosterone is not available
•Luteinizing hormone and follicle-stimulating hormone levels help distinguish primary from secondary hypogonadism: elevated gonadotropins with low testosterone suggest primary testicular failure; low or normal gonadotropins with low testosterone suggest secondary (central) dysfunction
•Prolactin should be measured if secondary hypogonadism is confirmed, since a prolactin-secreting pituitary adenoma is a treatable cause
•Symptom assessment is necessary alongside biochemistry; the Endocrine Society definition requires both low testosterone and symptoms consistent with hypogonadism, not a low number alone

The TTrials: what a coordinated series of randomized trials found

The Testosterone Trials, commonly abbreviated TTrials, were a coordinated set of seven placebo-controlled trials enrolling men 65 and older with low testosterone, published primarily in the New England Journal of Medicine and JAMA between 2016 and 2018. They were designed to address limitations of prior smaller trials by using a single shared coordinating center, standardized enrollment criteria, and a common placebo-controlled design. Approximately 790 men were enrolled across all seven trials.

The Sexual Function Trial found that testosterone replacement produced statistically significant improvements in sexual activity, libido, and erectile function compared with placebo. The Physical Function Trial found improvements in walking distance but the results were modest in clinical magnitude. The Vitality Trial found no statistically significant improvement in energy or fatigue with testosterone compared with placebo.

The Bone Trial found that testosterone produced significant increases in volumetric bone density and bone strength at the spine and hip. The Cognitive Function Trial found no benefit on cognitive function measures. The Anemia Trial found that testosterone increased hemoglobin and resolved anemia in a higher proportion of participants than placebo. The Cardiovascular Trial found progression of coronary artery plaque as measured by CT angiography was greater in the testosterone group than in the placebo group, a finding that contributed to ongoing safety questions that were later addressed in the TRAVERSE trial.

The TRAVERSE trial: cardiovascular safety resolved

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, was a large randomized controlled trial designed specifically to answer the cardiovascular safety question raised by earlier data. It enrolled 5,246 men aged 45 to 80 with hypogonadism, defined as two morning total testosterone measurements below 300 ng/dL, plus symptoms, who also had either established cardiovascular disease or high cardiovascular risk. Participants were randomized to transdermal testosterone gel or placebo and followed for a median of about 33 months.

The primary outcome was major adverse cardiovascular events: nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The TRAVERSE trial found that testosterone replacement was non-inferior to placebo on this outcome, providing the most definitive evidence to date that testosterone replacement at clinical doses in symptomatic hypogonadal men does not increase major cardiovascular events.

TRAVERSE secondary findings worth noting

While the primary cardiovascular endpoint was reassuring, the TRAVERSE trial reported higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group compared with placebo. These findings were secondary endpoints and the trial was not powered to detect differences in each individually, but they were statistically significant and represent safety signals that clinicians take into account when evaluating individual patients. The trial authors note these findings require further investigation.

The first author of the TRAVERSE trial was A. Michael Lincoff of the Cleveland Clinic, and the study was conducted in collaboration with Shalender Bhasin of Brigham and Women's Hospital, one of the leading researchers in testosterone and hypogonadism. The trial was funded in part by AbbVie, which markets a testosterone product, but was independently designed and analyzed. The lead investigators confirmed that the sponsor had no role in the decision to publish.

Testosterone, GLP-1, and the weight loss connection

One underappreciated area in men's metabolic health is what happens to testosterone when significant weight loss occurs, whether through lifestyle changes or GLP-1 receptor agonist therapy. Because the suppression of testosterone in obese men with secondary hypogonadism is substantially driven by excess adiposity and its metabolic consequences, correcting those conditions often raises testosterone without any direct hormonal intervention.

A study published in Endocrine Practice in 2020 examining testosterone changes in men undergoing a low-calorie dietary intervention found that substantial weight loss produced meaningful increases in total and free testosterone. The degree of testosterone improvement correlated with the magnitude of weight loss and the reduction in waist circumference. Research examining bariatric surgery outcomes has consistently shown testosterone normalization in a substantial proportion of men with pre-surgical hypogonadism.

GLP-1 receptor agonists have not been specifically studied for their effect on testosterone as a primary outcome in large trials. However, given the mechanism by which weight loss improves testosterone in obese men with secondary hypogonadism, it is biologically plausible that the substantial weight losses seen in STEP 1 and SURMOUNT-1 would produce similar improvements. This remains an area of active interest but the direct trial evidence is limited as of 2026.

•Bariatric surgery studies have reported testosterone increases averaging 8 to 12 nmol/L in severely obese men with pre-surgical low testosterone
•The magnitude of testosterone improvement after weight loss correlates more strongly with reduction in waist circumference than with total weight lost, consistent with the aromatase mechanism driven by visceral fat
•Testosterone replacement does not produce meaningful weight loss on its own; the TTrials Physical Function Trial and other studies found modest effects at best on body composition
•Combining testosterone replacement with weight loss interventions in men who have both conditions has been studied in small trials but large trial data are not yet available